Does the media refer more to ABCL or COGT?

In the previous week, AbCellera Biologics had 13 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for AbCellera Biologics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.64 beat AbCellera Biologics' score of 0.01 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MIRM or ABCL?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 15 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.01 beat Mirum Pharmaceuticals' score of -0.13 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer LNTH or ABCL?

In the previous week, Lantheus had 12 more articles in the media than AbCellera Biologics. MarketBeat recorded 27 mentions for Lantheus and 15 mentions for AbCellera Biologics. Lantheus' average media sentiment score of 0.35 beat AbCellera Biologics' score of 0.01 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BLTE or ABCL?

In the previous week, AbCellera Biologics had 11 more articles in the media than Belite Bio. MarketBeat recorded 15 mentions for AbCellera Biologics and 4 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.14 beat AbCellera Biologics' score of 0.01 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CGON or ABCL?

In the previous week, AbCellera Biologics had 4 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for AbCellera Biologics and 11 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.12 beat AbCellera Biologics' score of 0.01 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

AbCellera Biologics (ABCL) Competitors

$6.53 +0.61 (+10.30%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$6.63 +0.10 (+1.55%)

As of 08:10 AM Eastern

Compare

ABCL vs. COGT, MIRM, LNTH, BLTE, and CGON

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Belite Bio (BLTE), and CG Oncology (CGON).

How does AbCellera Biologics compare to Cogent Biosciences?

AbCellera Biologics (NASDAQ:ABCL) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AbCellera Biologics currently has a consensus target price of $9.40, indicating a potential upside of 43.95%. Cogent Biosciences has a consensus target price of $45.90, indicating a potential upside of 9.81%. Given AbCellera Biologics' higher possible upside, equities analysts plainly believe AbCellera Biologics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

AbCellera Biologics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	26.54	-$146.41M	-$0.48	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, AbCellera Biologics had 13 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for AbCellera Biologics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.64 beat AbCellera Biologics' score of 0.01 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.22% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.22%	-12.29%
Cogent Biosciences	N/A	-104.27%	-54.64%

AbCellera Biologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

AbCellera Biologics beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Mirum Pharmaceuticals currently has a consensus target price of $137.33, suggesting a potential upside of 45.93%. AbCellera Biologics has a consensus target price of $9.40, suggesting a potential upside of 43.95%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

61.4% of AbCellera Biologics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 15 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.01 beat Mirum Pharmaceuticals' score of -0.13 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.01	-$23.36M	-$13.61	N/A
AbCellera Biologics	$75.13M	26.54	-$146.41M	-$0.48	N/A

Mirum Pharmaceuticals has a net margin of -139.18% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.22% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-26.88%	-9.06%
AbCellera Biologics	-248.83%	-17.22%	-12.29%

Summary

Mirum Pharmaceuticals beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Lantheus has a net margin of 18.05% compared to AbCellera Biologics' net margin of -248.83%. Lantheus' return on equity of 29.32% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
AbCellera Biologics	-248.83%	-17.22%	-12.29%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lantheus has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.15	24.35
AbCellera Biologics	$75.13M	26.54	-$146.41M	-$0.48	N/A

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Lantheus had 12 more articles in the media than AbCellera Biologics. MarketBeat recorded 27 mentions for Lantheus and 15 mentions for AbCellera Biologics. Lantheus' average media sentiment score of 0.35 beat AbCellera Biologics' score of 0.01 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lantheus presently has a consensus price target of $108.11, suggesting a potential upside of 6.97%. AbCellera Biologics has a consensus price target of $9.40, suggesting a potential upside of 43.95%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Lantheus beats AbCellera Biologics on 11 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. Belite Bio's return on equity of -13.14% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
AbCellera Biologics	-248.83%	-17.22%	-12.29%

Belite Bio has higher earnings, but lower revenue than AbCellera Biologics. Belite Bio is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
AbCellera Biologics	$75.13M	26.54	-$146.41M	-$0.48	N/A

Belite Bio has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 26.35%. AbCellera Biologics has a consensus target price of $9.40, suggesting a potential upside of 43.95%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, AbCellera Biologics had 11 more articles in the media than Belite Bio. MarketBeat recorded 15 mentions for AbCellera Biologics and 4 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.14 beat AbCellera Biologics' score of 0.01 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CG Oncology has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.22% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
AbCellera Biologics	-248.83%	-17.22%	-12.29%

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 9.19%. AbCellera Biologics has a consensus price target of $9.40, suggesting a potential upside of 43.95%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

CG Oncology has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

AbCellera Biologics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,634.10	-$160.99M	-$2.33	N/A
AbCellera Biologics	$75.13M	26.54	-$146.41M	-$0.48	N/A

In the previous week, AbCellera Biologics had 4 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for AbCellera Biologics and 11 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.12 beat AbCellera Biologics' score of 0.01 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats CG Oncology on 12 of the 17 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.81B	$3.61B	$6.95B	$12.87B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-12.09	8.36	271.22	25.30
Price / Sales	26.54	1,267.45	653.46	106.23
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	2.02	18.00	13.13	6.13
Net Income	-$146.41M	-$13.22M	$3.46B	$342.95M
7 Day Performance	14.36%	4.41%	3.38%	3.19%
1 Month Performance	-15.08%	-4.92%	-2.70%	-1.98%
1 Year Performance	54.01%	56.63%	75.98%	21.11%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.7949 of 5 stars	$6.53 +10.3%	$9.40 +44.0%	+58.5%	$1.81B	$75.13M	N/A	500	Trending News Earnings Report Analyst Forecast Gap Down
COGT Cogent Biosciences	1.527 of 5 stars	$39.34 -4.9%	$45.90 +16.7%	+281.0%	$6.72B	N/A	N/A	80	Positive News Upcoming Earnings
MIRM Mirum Pharmaceuticals	2.712 of 5 stars	$108.37 -3.7%	$143.40 +32.3%	+76.3%	$6.59B	$569.61M	N/A	140	Trending News Earnings Report Analyst Forecast Insider Trade
LNTH Lantheus	2.8666 of 5 stars	$100.16 -0.8%	$109.71 +9.5%	+94.9%	$6.51B	$1.54B	24.09	1,193	Earnings Report Analyst Downgrade
BLTE Belite Bio	3.4935 of 5 stars	$156.63 -2.1%	$203.00 +29.6%	+136.3%	$6.28B	N/A	N/A	10	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. COGT, MIRM, LNTH, BLTE, and CGON

How does AbCellera Biologics compare to Cogent Biosciences?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Lantheus?

Summary

How does AbCellera Biologics compare to Belite Bio?

Summary

How does AbCellera Biologics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. COGT, MIRM, LNTH, BLTE, and CGON

How does AbCellera Biologics compare to Cogent Biosciences?

Do insiders and institutionals hold more shares of ABCL or COGT?

Do analysts prefer ABCL or COGT?

Which has higher valuation and earnings, ABCL or COGT?

Does the media refer more to ABCL or COGT?

Is ABCL or COGT more profitable?

Which has more risk & volatility, ABCL or COGT?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or ABCL?

Do insiders & institutionals have more ownership in MIRM or ABCL?

Does the media prefer MIRM or ABCL?

Which has more risk & volatility, MIRM or ABCL?

Which has stronger valuation & earnings, MIRM or ABCL?

Is MIRM or ABCL more profitable?

Summary

How does AbCellera Biologics compare to Lantheus?

Is LNTH or ABCL more profitable?

Do insiders and institutionals have more ownership in LNTH or ABCL?

Which has better earnings and valuation, LNTH or ABCL?

Which has more risk and volatility, LNTH or ABCL?

Does the media prefer LNTH or ABCL?

Do analysts recommend LNTH or ABCL?

Summary

How does AbCellera Biologics compare to Belite Bio?

Do institutionals & insiders have more ownership in BLTE or ABCL?

Is BLTE or ABCL more profitable?

Which has higher valuation & earnings, BLTE or ABCL?

Which has more volatility & risk, BLTE or ABCL?

Do analysts rate BLTE or ABCL?

Does the media prefer BLTE or ABCL?

Summary

How does AbCellera Biologics compare to CG Oncology?

Do institutionals and insiders have more ownership in CGON or ABCL?

Is CGON or ABCL more profitable?

Do analysts prefer CGON or ABCL?

Which has more volatility & risk, CGON or ABCL?

Which has higher valuation and earnings, CGON or ABCL?

Does the media refer more to CGON or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools